Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in...
Mabwell Bioscience Receives FDA Green Light for B7-H3 Targeting ADC 7MW3711
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a...
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of...
Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC
Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...
Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...
Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...
Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...
Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...
ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL
ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...
Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards
The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...
AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...
Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...
China’s CDE Issues Guiding Principles for ADC Research and Evaluation
China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...
GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book
Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...
Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies
Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...
Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint
Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...
China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...
GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September
The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...
National Health Commission Notification Signals New Poliovirus Containment Measures
The National Health Commission (NHC) has issued a notification announcing the establishment of the National...